A multisite, naturalistic, observational study of TMS for patients with pharmacoresistant major depressive disorder – 2014

A multisite, Naturalistic, Observational Study of TMS for pharma resistant Depression PDF

David L. Dunner, MD; Scott T. Aaronson, MD; Harold A. Sackeim, PhD; Philip G. Janicak, MD; Linda L. Carpenter, MD; Terrence Boyadjis, MD; David G. Brock, MD; Dafna Bonneh-Barkay, PhD; Ian A. Cook, MD; Karl Lanocha, MD; H. Brent Solvason, MD, PhD; and Mark A. Demitrack, MD

Compared with pre-TMS baseline, there was a statistically significant reduction in mean total scores on
the Clinical Global Impressions-Severity of Illness scale (primary outcome), 9-Item Patient Health Questionnaire, and Inventory of Depressive Symptoms-Self Report (IDS-SR) at the end of acute treatment (all P < .0001), which was sustained throughout follow-up (all P < .0001). The proportion of patients who achieved remission at the conclusion of acute treatment remained similar at conclusion of the long-term follow-up. Among 120 patients who met IDS-SR response or remission criteria at the end of acute treatment, 75 (62.5%) continued to meet response criteria throughout long-term follow-up. After the first month, when the majority of acute TMS tapering was completed, 93 patients (36.2%) received reintroduction of TMS. In this group, the mean (SD) number of TMS treatment days was 16.2 (21.1).

Related Posts